UPDATE: JMP Securities Reiterates on Depomed Following Acquisition of Migraine Asset

In a report published Wednesday, JMP Securities analyst Jason N. Butler reiterated a Market Outperform rating on Depomed (NASDAQ: DEPO ), and raised the price target from $10.00 to $11.00. In the report, JMP Securities noted, “Acquisition of migraine asset makes strategic and financial sense; reiterate Market Outperform rating and